As Pfizer Faces Brand Drug Challenges, Management Pushes Cost Cuts
This article was originally published in The Pink Sheet Daily
Executive Summary
Executives head off questions about dramatic transformational changes during third quarter earnings call; Fablyn is delayed three months by FDA.